# Short and Optimal Duration of Dual Antiplatelet Therapy Study

Study · id `cardio:ct-nct01659034` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT01659034](<https://clinicaltrials.gov/study/NCT01659034>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT01659034

Browse, organ or system: Heart  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1525 participants.

## Technical summary

Registry record NCT01659034. Allocation not applicable; no masking; primary purpose treatment. Start 2012-09 (registry gives no type); primary completion 2014-10 (actual). Results not posted.

## Key facts

- Design: Interventional study; allocation not applicable; no masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 1525 participants (enrolled count; ClinicalTrials.gov record NCT01659034, source copy `cardio:ctgov-nct01659034-2015-12-10`, retrieved 2026-10-26)
- Start date: 2012-09 (registry gives no type) (ClinicalTrials.gov record NCT01659034, source copy `cardio:ctgov-nct01659034-2015-12-10`, retrieved 2026-10-26)
- Primary completion: 2014-10 (actual) (ClinicalTrials.gov record NCT01659034, source copy `cardio:ctgov-nct01659034-2015-12-10`, retrieved 2026-10-26)
- Completion: 2014-12 (actual) (ClinicalTrials.gov record NCT01659034, source copy `cardio:ctgov-nct01659034-2015-12-10`, retrieved 2026-10-26)
- Countries: Japan (ClinicalTrials.gov record NCT01659034, source copy `cardio:ctgov-nct01659034-2015-12-10`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct01659034-2015-12-10`, retrieved 2026-10-26)

## The registry's words

- Brief title: Short and Optimal Duration of Dual Antiplatelet Therapy Study
- Acronym: STOPDAPT
- Condition: Coronary Artery Disease
- Intervention (Drug): Thienopyridine for 3 months
- Lead sponsor: Takeshi Morimoto
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Coronary artery disease (`cardio:coronary-artery-disease`)
- Registry lists this organization as the lead sponsor: Takeshi Morimoto (`cardio:org-takeshi-morimoto`)

## Provenance

Content hash: 5a58c69f65d949bab68eb9b8c973584ac519e3ef6e749f9d6174ee00aab09f5b
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
